Rtw Investments is Buying Ptc Therapeutics Inc. (NASDAQ:PTCT) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ptc Therapeutics Inc. (NASDAQ:PTCT) reported that Rtw Investments, Lp. has picked up 1,794,336 of common stock as of 2017-04-21.
The acquisition brings the aggregate amount owned by Rtw Investments, Lp. to a total of 1,794,336 representing less than 5.2% stake in the company.
For those not familiar with the company, PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
A glance at Ptc Therapeutics Inc. (NASDAQ:PTCT)’s key stats reveals a current market capitalization of 392.91 Million based on 34.56 Million shares outstanding and a price at last close of $11.37 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-03 Rothera picked up 2,000 at a purchase price of $6.23. This brings their total holding to 5,125 as of the date of the filing.
On the sell side, the most recent transaction saw Almstead unload 78 shares at a sale price of $11.82. This brings their total holding to 2,687.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ptc Therapeutics Inc. (NASDAQ:PTCT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Dynatronics Corp (NASDAQ:DYNT) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Dynatronics Corp (NASDAQ:DYNT) reported that Provco Ventures 1 Lp has picked up 8,110,472 of common stock as of 2017-04-19.
The acquisition brings the aggregate amount owned by Provco Ventures 1 Lp to a total of 8,110,472 representing a 24.0% stake in the company.
For those not familiar with the company, Dynatronics Corporation is a manufacturer and distributor of physical medicine products. The Company’s products include a line of medical equipment for physical medicine applications, including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. Its products are used by physical therapists, chiropractors, sports medicine practitioners, podiatrists, physicians and other physical medicine professionals. Its physical medicine products include therapeutic modalities, such as Dynatron Solaris, including electrotherapy and thermal therapy, and 25 Series, including electrotherapy and ultrasound; manufactured capital products, including traction systems and wood furniture; manufactured supplies, including cold packs, straps, wedges, bolsters and mats; distributed capital products, including hydrotherapy, weight training equipment and pilates, and distributed supplies, including clinical accessories, sports med and taping products, lotions and gels.
A glance at Dynatronics Corp (NASDAQ:DYNT)’s key stats reveals a current market capitalization of 8.55 Million based on 3.04 Million shares outstanding and a price at last close of $2.85 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2011-03-29, Beardall picked up 1,400 at a purchase price of $0.97. This brings their total holding to 177,588 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Dynatronics Corp (NASDAQ:DYNT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Flynn James E Picked Mannkind Corp (NASDAQ:MNKD) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mannkind Corp (NASDAQ:MNKD) reported that Flynn James E has picked up 5,217,391 of common stock as of 2017-04-19.
The acquisition brings the aggregate amount owned by Flynn James E to a total of 5,217,391 representing a 5.17% stake in the company.
For those not familiar with the company, MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
A glance at Mannkind Corp (NASDAQ:MNKD)’s key stats reveals a current market capitalization of 113.14 Million based on 95.78 Million shares outstanding and a price at last close of $1.22 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-03, Pfeffer picked up 4,540 at a purchase price of $0.54. This brings their total holding to 403,085 as of the date of the filing.
On the sell side, the most recent transaction saw Alinaya unload 6,294 shares at a sale price of $1.06. This brings their total holding to 131,413.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Mannkind Corp (NASDAQ:MNKD) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Chu James Michael is Buying Noodles & Co. (NASDAQ:NDLS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Noodles & Co. (NASDAQ:NDLS) reported that Chu James Michael has picked up 11,092,853 of common stock as of 2017-04-12.
The acquisition brings the aggregate amount owned by Chu James Michael to a total of 11,092,853 representing a 28.1% stake in the company.
For those not familiar with the company, Noodles & Company develops and operates fast casual restaurants. The Company’s menu includes a range of cooked-to-order dishes, including noodles and pasta, soups, salads, sandwiches and appetizers. The Company has approximately 490 restaurants, including 420 Company-owned and 70 franchised locations, across 40 states, the District of Columbia and one Canadian province. The Company offers over 30 globally inspired Asian, Mediterranean and American dishes together on a single menu. The Company offers approximately 10 fresh vegetables and six proteins, including marinated steak, naturally raised pork, chicken, meatballs, shrimp and organic tofu. The Company offers Kids Meals, which includes sides, such as broccoli, carrots, fruit, applesauce and a portion of its housemade rice crispy treat. The Company’s restaurants’ locations include Arizona, California, Colorado, Delaware, New York, North Dakota, Ohio, Texas, Utah, Virginia, Washington and Wisconsin.
A glance at Noodles & Co. (NASDAQ:NDLS)’s key stats reveals a current market capitalization of 154.87 Million based on 26.35 Million shares outstanding and a price at last close of $5.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-12-31, Mears picked up 5,000 at a purchase price of $9.98. This brings their total holding to 5,000 as of the date of the filing.
On the sell side, the most recent transaction saw Mears unload 5,000 shares at a sale price of $9.69. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Noodles & Co. (NASDAQ:NDLS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Capital World Investors Picked Up Humana Inc. (NYSE:HUM) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Humana Inc. (NYSE:HUM) reported that Capital World Investors has picked up 14,602,995 of common stock as of 2017-04-10.
The acquisition brings the aggregate amount owned by Capital World Investors to a total of 14,602,995 representing a 10.1% stake in the company.
For those not familiar with the company, Humana Inc. is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. The Group segment consists of employer group commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and voluntary insurance benefits, as well as administrative services only (ASO) products. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Other Businesses segment includes its closed-block long-term care insurance policies.
A glance at Humana Inc. (NYSE:HUM)’s key stats reveals a current market capitalization of 30.14 Billion based on 144.28 Million shares outstanding and a price at last close of $210.75 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2011-07-29, Damelio picked up 526 at a purchase price of $79.83. This brings their total holding to 20,634 as of the date of the filing.
On the sell side, the most recent transaction saw Bilney unload 4,348 shares at a sale price of $213.80. This brings their total holding to 13,578.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Humana Inc. (NYSE:HUM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Kingstown Capital Partners is Buying Novelion Therapeutics Inc. (NASDAQ:NVLN) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Novelion Therapeutics Inc. (NASDAQ:NVLN) reported that Kingstown Capital Partners, Llc. has picked up 358,460 of common stock as of 2017-04-05.
The acquisition brings the aggregate amount owned by Kingstown Capital Partners, Llc. to a total of 358,460 representing a 1.9% stake in the company.
For those not familiar with the company, Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
A glance at Novelion Therapeutics Inc. (NASDAQ:NVLN)’s key stats reveals a current market capitalization of 195.73 Million based on 18.53 Million shares outstanding and a price at last close of $10.65 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-09-15, Stonepine picked up 14,928 at a purchase price of $1.55. This brings their total holding to 5,778,496 as of the date of the filing.
On the sell side, the most recent transaction saw Axial unload 8,865,036 shares at a sale price of $3.47. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Novelion Therapeutics Inc. (NASDAQ:NVLN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Entellus Medical Inc. (NASDAQ:ENTL) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Entellus Medical Inc. (NASDAQ:ENTL) reported that Discovery Group I, Llc. has picked up 1,418,715 of common stock as of 2017-03-06.
The acquisition brings the aggregate amount owned by Discovery Group I, Llc. to a total of 1,418,715 representing a 6.5% stake in the company.
For those not familiar with the company, Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company’s XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company’s PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
A glance at Entellus Medical Inc. (NASDAQ:ENTL)’s key stats reveals a current market capitalization of 286.30 million based on 21.88 Million shares outstanding and a price at last close of $13.32 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-02-03, Split picked up 352,941 at a purchase price of $17.00. This brings their total holding to 3,156,731 as of the date of the filing.
On the sell side, the most recent transaction saw Essex unload 16,521 shares at a sale price of $17.00. This brings their total holding to 91,808.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Entellus Medical Inc. (NASDAQ:ENTL) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.